Cellectis (CLLS) Change in Cash (2015 - 2026)
Cellectis (CLLS) posted Change in Cash of -$26.5 million for Q1 2026, down 433.06% on a QoQ basis from $7.9 million in Q4 2025, and down 55.48% year-over-year from -$59.5 million in Q1 2025.
Cellectis (CLLS) has 12 years of Change in Cash data on file, last reported at -$26.5 million in Q1 2026.
- In Q1 2026, Change in Cash fell 55.48% year-over-year to -$26.5 million; the TTM figure through Mar 2026 stood at -$95.1 million (down 1757.56% YoY), while the FY2025 annual figure was -$85.6 million, down 1021.43% from the prior year.
- Change in Cash eased to -$26.5 million in Q1 2026, from $7.9 million in the prior quarter.
- Across five years, Change in Cash topped out at $67.6 million in Q4 2023 and bottomed at -$67.3 million in Q2 2025.
- A 5-year average of -$8.8 million and a median of -$13.5 million in 2024 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2024 — Change in Cash jumped 2495.06% — and 2025, when it sank 377.38%.
- Year by year, Change in Cash stood at -$6.4 million in 2022, then soared by 1152.81% to $67.6 million in 2023, then slumped by 120.37% to -$13.8 million in 2024, then soared by 157.68% to $7.9 million in 2025, then sank by 433.06% to -$26.5 million in 2026.
- The last three Change in Cash figures came in at -$26.5 million (Q1 2026), $7.9 million (Q4 2025), and -$9.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 623.00 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 417.10 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -153.10 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 53.61 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -26.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.48 Mn |
| Dec 31, 2025 | 7.95 Mn |
| Sep 30, 2025 | -9.27 Mn |
| Jun 30, 2025 | -67.30 Mn |
| Mar 31, 2025 | -17.03 Mn |
| Dec 31, 2024 | -13.78 Mn |
| Sep 30, 2024 | 12.29 Mn |
| Jun 30, 2024 | 24.26 Mn |
| Mar 31, 2024 | -13.47 Mn |
| Dec 31, 2023 | 67.64 Mn |
| Sep 30, 2023 | -15.71 Mn |
| Jun 30, 2023 | -1.01 Mn |
| Mar 31, 2023 | -8.32 Mn |
| Dec 31, 2022 | -6.43 Mn |
| Sep 30, 2022 | -30.22 Mn |
| Jun 30, 2022 | -22.50 Mn |
| Mar 31, 2022 | -29.92 Mn |
| Dec 31, 2021 | -22.71 Mn |
| Sep 30, 2021 | -36.57 Mn |
| Jun 30, 2021 | 40.35 Mn |
| Mar 31, 2021 | -30.83 Mn |
| Dec 31, 2020 | -23.95 Mn |
| Sep 30, 2020 | -6.79 Mn |
| Jun 30, 2020 | -27.55 Mn |
| Mar 31, 2020 | -48.99 Mn |
| Dec 31, 2019 | -6.44 Mn |
| Sep 30, 2019 | -49.28 Mn |
| Jun 30, 2019 | -25.03 Mn |
| Mar 31, 2019 | -28.13 Mn |
| Dec 31, 2018 | -22.49 Mn |
| Sep 30, 2018 | 5.28 Mn |
| Jun 30, 2018 | 238.24 Mn |
| Mar 31, 2018 | -17.04 Mn |
| Dec 31, 2017 | -9.07 Mn |
| Sep 30, 2017 | 29.82 Mn |
| Jun 30, 2017 | -29.49 Mn |
| Mar 31, 2017 | -18.81 Mn |
| Dec 31, 2016 | 49.18 Mn |
| Sep 30, 2016 | 6.58 Mn |
| Jun 30, 2016 | -16.01 Mn |
| Mar 31, 2016 | -123.86 Mn |
| Sep 30, 2015 | -4.80 Mn |
| Jun 30, 2015 | 194.26 Mn |
| Mar 31, 2015 | -4.35 Mn |